PLATELET DERIVED GROWTH FACTOR IN DIABETIC LOWER EXTREMITY ULCER: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY IN INDIAN CONDITIONAbstract
Background-In September 2012, the world health organization reported a global prevalence of diabetes exceeding 300 million people, predicting a further 60-70% increase by the year 2030, which means India alone will have 100 million people by year 2030. Wound healing is problematic in diabetic patients. Encouraging results have shown that PDGF application is better than good wound care alone. But the evidence to demonstrate the safety and efficacy of PDGF in Diabetic ulcer is scanty. Aim-To Study the Efficacy of Platelet Derived Growth Factor in Diabetic Lower Extremity Ulcer. Methods-This study was a prospective, double blind, and placebo controlled study. A total of 29 patients with 35 ulcers were included and divided in case and control group. The study medication was administered in conjunction with standardized good wound care for 24 weeks or until target ulcer healed. Results-It was found that 74.2% of ulcers were neuropathic while 48.3% patients had foot deformity in this study. At the end of 24 weeks 100% ulcers in group receiving PDGF completely healed while group receiving Placebo 76.4% ulcers healed. Mean of time to achieve wound healing was 9 + 7.1 weeks in ulcer receiving PDGF gel and they healed 50% faster as compared to ulcers receiving placebo. Conclusion– There was no relation of type, duration, ABI, neurological deficit, type of ulcer, foot deformity, wagner grade, edema, infection, duration of ulcer with time to achieve wound closure. This meant that PDGF was solely responsible for the ulcers to heal 50% faster.
Abhishek Samuel *, Anupam Mahajan, Maharaj K. Mam and Jeewan S. Prakash
Department of Orthopaedics, Christian Medical College, Ludhiana, Punjab, India
20 April, 2016
13 July, 2016
23 August, 2016
01 September 2016